Updated:
Cellular Dynamics International
James Thomson founded CDI to scale iPSC-derived human cells for pharma drug screens.
Cellular Dynamics International
Cellular Dynamics International launched in 2004 in Madison, Wisconsin, commercializing the stem-cell breakthroughs of founder James Thomson and his University of Wisconsin colleagues. The company makes functional human cells—cardiomyocytes, neurons, hepatocytes—from induced pluripotent stem cells (iPSCs) at industrial scale. This manufacturing capability lets pharmaceutical researchers test drug toxicity on authentic human tissue rather than relying on animal models or immortalized cell lines. In 2015, Fujifilm acquired CDI for $307 million in a deal that signaled the conglomerate's long-term pivot from photographic film into regenerative medicine (per Fujifilm Holdings, 2015). CDI supplies its iPSC-derived cells to most of the top 20 global pharmaceutical companies for preclinical safety pharmacology and drug discovery. The firm's core product lines—including iCell Cardiomyocytes, iCell Neurons, and iCell Hepatocytes—are integrated into high-throughput screening platforms used to identify cardiotoxicity and neurotoxicity before human trials begin. Beyond catalog products, CDI performs custom disease modeling, creating cell lines from patients with specific genetic conditions to test candidate therapies. The firm also partners with academic institutions and contract research organizations across North America, Europe, and Japan to embed its cells in next-generation toxicology workflows. Following the Fujifilm acquisition, CDI scaled its Madison manufacturing facility and expanded its commercial footprint through Fujifilm's existing life-science distribution channels. The company now operates within Fujifilm's Life Sciences division, which also includes Irvine Scientific and Fujifilm Wako Chemicals, creating a vertically integrated supply chain from raw materials to finished cell-based assays. In 2022, the firm appointed Kazuyoshi Kuwabara as President and CEO, continuing its integration into Fujifilm's broader regenerative medicine strategy (per the firm's official communications, 2022). CDI's structural advantage is its position at the intersection of Japanese industrial manufacturing discipline and the Madison stem-cell research ecosystem. Unlike most biotech platform companies that seek to develop their own therapies, CDI functions as a neutral manufacturing supplier to the entire drug-development industry. This supplier-agnostic architecture shields the firm from the binary risk of clinical trials while generating revenue from the global trend toward human-relevant preclinical models, accelerated by the FDA Modernization Act 2.0 which removed the mandate for animal testing in drug development.
General information
Firm type
Asset Manager
Year founded
2004
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Madison
Corporate office
Madison, WI, United States
Principals
James Thomson
Founder
Kazuyoshi Kuwabara
President & CEO
Sector focus
Frequently asked questions
Who founded Cellular Dynamics International and what was the core technology?
CDI was founded in 2004 by Dr. James Thomson, a University of Wisconsin developmental biologist who in 1998 became the first scientist to isolate human embryonic stem cells, and in 2007 developed methods to reprogram adult cells into induced pluripotent stem cells (iPSCs). CDI commercialized the iPSC technology to manufacture consistent batches of human cells—initially cardiomyocytes, then neurons, hepatocytes, and others—for use in pharmaceutical research and toxicology screening.
How does CDI's relationship with Fujifilm shape its operations?
Fujifilm Holdings acquired CDI in 2015 for $307 million, and the company now operates as a subsidiary within Fujifilm's Life Sciences division. This integration provides CDI with Fujifilm's global distribution network, manufacturing expertise, and balance-sheet support, while allowing the Madison operation to maintain a distinct brand identity and continue supplying cells to Fujifilm's pharmaceutical competitors on a non-exclusive basis.
What is CDI's business model—does it develop its own therapies?
No. CDI is a B2B supplier of human cell products and services to the pharmaceutical and biotechnology industries. It does not pursue internal therapeutic development. Its revenue comes from selling catalog iPSC-derived cells, custom disease-modeling services, and toxicity-screening platforms to drug developers. This model generates revenue independent of clinical-trial outcomes for the therapies tested using its cells.
What sectors does CDI primarily serve?
CDI serves the preclinical drug-discovery and safety-pharmacology sectors. Its primary customers are pharmaceutical companies screening for cardiotoxicity, neurotoxicity, and hepatotoxicity. Secondary applications include academic researchers studying genetic disease mechanisms and CROs incorporating human iPSC-derived cells into their screening service offerings.
Where are CDI's cells manufactured and how are they distributed?
The iPSC-derived cells are manufactured at CDI's headquarters facility in Madison, Wisconsin, and distributed globally. Fujifilm's existing life-science logistics network, including subsidiaries in Japan and Europe, handles international distribution. The Madison facility's capacity was upgraded following the Fujifilm acquisition to support increasing demand from large pharmaceutical accounts.
How does CDI differentiate from competitors in the iPSC space?
CDI's differentiation comes from being the first to commercialize iPSC technology at scale, its manufacturing quality-control systems built over two decades, and its structural position as a neutral supplier that does not compete with its customers on therapeutic development. The Fujifilm balance sheet also provides stability that many independent biotech platform companies lack.
What is the significance of the FDA Modernization Act 2.0 for CDI's business?
The FDA Modernization Act 2.0, signed into law in late 2022, removed the federal mandate that drug candidates must undergo animal testing before human trials. This regulatory shift opens the door for sponsors to use alternative methods—including iPSC-derived human cell assays—in preclinical safety submissions. As a major supplier of those assays, CDI is positioned to benefit from increased adoption of cell-based toxicology models.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: